LCM
EBS icon

Laurion Capital Management’s Emergent Biosolutions EBS Stock Holding History

Laurion Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,302
Closed -$132K – 394
2024
Q2 		$132K Buy
+19,302
New +$83.1K ﹤0.01% 500
2023
Q4 		– Sell
-11,012
Closed -$37.4K – 512
2023
Q3 		$37.4K Buy
+11,012
New +$61K ﹤0.01% 468
2019
Q4 		– Sell
-7,200
Closed -$376K – 967
2019
Q3 		$376K Buy
+7,200
New +$335K ﹤0.01% 819
2017
Q3 		– Sell
-6,311
Closed -$214K – 1644
2017
Q2 		$214K Buy
+6,311
New +$195K ﹤0.01% 1528

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Laurion Capital Management's EBS Position: Q3 2024 in Review

Laurion Capital Management sold out of Emergent Biosolutions (EBS) in Q3 2024, closing a stake of 19,302 shares — an estimated $132K sold.

Laurion Capital Management first reported a position in EBS in Q2 2017 and held it in 4 quarters. The position peaked at $376K in Q3 2019. 140 funds tracked by Wall St. Rank hold EBS as of Q3 2024.

  • Laurion Capital Management reported no remaining Emergent Biosolutions position as of Q3 2024 after selling out during the quarter.
  • Laurion Capital Management sold 19,302 Emergent Biosolutions shares in Q3 2024, an estimated $132K.
  • Laurion Capital Management first reported a position in Emergent Biosolutions in Q2 2017 and held it in 4 quarters.
  • Laurion Capital Management's Emergent Biosolutions position peaked at $376K in Q3 2019.
  • 140 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2024.

Based on Laurion Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.